A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of tenofovir DF [tenofovir disoproxil fumarate] as part of an optimized antiretroviral regimen in HIV-1-infected adolescents.

Trial Profile

A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of tenofovir DF [tenofovir disoproxil fumarate] as part of an optimized antiretroviral regimen in HIV-1-infected adolescents.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top